• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cerus Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/9/25 1:39:17 PM ET
    $CERS
    EDP Services
    Technology
    Get the next $CERS alert in real time by email
    8-K
    false000102021400010202142025-06-032025-06-03

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 3, 2025

    Cerus Corporation

    (Exact name of Registrant as Specified in Its Charter)

    Delaware

    000-21937

    68-0262011

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    1220 Concord Ave., Suite 600

    Concord, California

    94520

    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (925) 288-6000

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    CERS

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    (e) On June 3, 2025, the stockholders of Cerus Corporation (the “Company”) approved an amendment and restatement of the Company’s 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”). The material terms of the 2024 Equity Incentive Plan are described in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 23, 2025 (the “Proxy Statement”), in the section entitled “Proposal No. 2 – Amendment and Restatement of the Company’s 2024 Equity Incentive Plan” on pages 22 to 35, which description is incorporated herein by reference.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 3, 2025, the Company held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of votes withheld, abstentions and broker non-votes with respect to each matter, as applicable. A more complete description of each matter is set forth in the Proxy Statement.

     

    Proposal 1

     

    The Company’s stockholders elected each of the two nominees named below to the Board of Directors to serve until the 2028 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified.

     

    Nominee

    For

    Withheld

    Broker Non-Votes

    Jami Dover Nachtsheim

    107,020,992

    7,011,149

    44,116,421

    Hua Shan, MD, Ph.D.

    111,424,285

    2,607,856

    44,116,421

     

    Proposal 2

     

    The Company’s stockholders approved amendment and restatement of the Company’s 2024 Equity Incentive Plan.

     

    For

    Against

    Abstain

    Broker Non-Votes

    74,344,720

    39,504,222

    183,199

    44,116,421

     

    Proposal 3

     

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.

     

    For

    Against

    Abstain

    Broker Non-Votes

    104,504,639

    9,321,156

    206,346

    44,116,421

     

    Proposal 4

     

    The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the Company for its fiscal year ending December 31, 2025.

     

    For

    Against

    Abstain

    153,189,590

    4,332,938

    626,034

     

    No other matters were submitted for stockholder action at the Annual Meeting.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     


     

     

    104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

     


     

    SIGNATURE

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Dated: June 9, 2025

     

    CERUS CORPORATION

     

    By: /s/ Chrystal N. Jensen

    Chrystal N. Jensen

    Chief Legal Officer and General Counsel

     

     

     


    Get the next $CERS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERS

    DatePrice TargetRatingAnalyst
    4/12/2024$5.00Buy
    Craig Hallum
    1/20/2023Buy → Neutral
    BTIG Research
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CERS
    SEC Filings

    See more
    • Cerus Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - CERUS CORP (0001020214) (Filer)

      6/9/25 1:39:17 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SD filed by Cerus Corporation

      SD - CERUS CORP (0001020214) (Filer)

      5/30/25 4:01:40 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form DEFA14A filed by Cerus Corporation

      DEFA14A - CERUS CORP (0001020214) (Filer)

      5/23/25 12:01:02 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Cerus with a new price target

      Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

      4/12/24 8:00:30 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by BTIG Research

      BTIG Research downgraded Cerus from Buy to Neutral

      1/20/23 10:02:56 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus downgraded by Stephens with a new price target

      Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

      1/17/23 7:57:35 AM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Financials

    Live finance-specific insights

    See more
    • Cerus Corporation Announces First Quarter 2025 Financial Results

      First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an

      5/1/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation to Release First Quarter 2025 Financial Results on May 1, 2025

      Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay wi

      4/17/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results

      Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively, from Prior Year Periods Fourth straight quarter of positive operating cash flows Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights include: Total revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %): Three Months Ended           Twelve Months Ended         December 31,   Change   December 31,   Change   Unaudited  

      2/20/25 4:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cerus Corporation to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

      Cerus Corporation (NASDAQ:CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at ir.cerus.com. A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, Ca

      6/3/25 4:30:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Presents Clinical Data for INTERCEPT Blood System at the 35th Regional International Society of Blood Transfusion Congress in Milan

      Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells Cerus Corporation (NASDAQ:CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to June 4, 2025, in Milan. "The breadth of data being presented this year underscores the broad applicability of the INTERCEPT system for platelets, plasma, and cryoprecipitated fibrinogen complex as well as the potential benefit for red blood cells," said Richard J. Benjamin, Cerus' chief medical officer. "Importantly, w

      5/29/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device

      France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma Cerus Corporation (NASDAQ:CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). The INT200, the Company's next generation LED-based illumination device, was developed as the new foundational platform for the INTERCEPT Blood System, with input and feedback from global customers to enhance daily blood center operations. The contemporary vertical configuration is designed to improve workflow and ergonomics while freeing u

      5/28/25 8:30:00 AM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      1/2/25 5:46:11 PM ET
      $CERS
      EDP Services
      Technology
    • Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/14/24 6:30:46 PM ET
      $CERS
      EDP Services
      Technology
    • Nachtsheim Jami K bought $3,578 worth of shares (2,000 units at $1.79), increasing direct ownership by 2% to 108,362 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      5/13/24 5:09:19 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cerus Corporation

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      11/12/24 9:53:11 AM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/14/24 4:21:51 PM ET
      $CERS
      EDP Services
      Technology
    • SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

      SC 13G/A - CERUS CORP (0001020214) (Subject)

      2/13/24 5:01:03 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h

      7/2/24 4:00:00 PM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

      Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w

      9/27/23 8:30:00 AM ET
      $CERS
      EDP Services
      Technology
    • Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

      Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co

      7/5/22 5:00:00 PM ET
      $CERS
      EDP Services
      Technology

    $CERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Witney Frank was granted 60,000 shares, increasing direct ownership by 27% to 280,059 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:53:35 PM ET
      $CERS
      EDP Services
      Technology
    • Director Moore Timothy L. was granted 60,000 shares, increasing direct ownership by 41% to 205,073 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:48:52 PM ET
      $CERS
      EDP Services
      Technology
    • Director Swisher Daniel N Jr was granted 60,000 shares, increasing direct ownership by 41% to 207,045 units (SEC Form 4)

      4 - CERUS CORP (0001020214) (Issuer)

      6/4/25 6:44:28 PM ET
      $CERS
      EDP Services
      Technology